Ozempic is highly effective for its approved purpose of lowering blood sugar in type 2 diabetes, and it produces significant weight loss as a secondary benefit. In clinical trials, the 1.0 mg dose lowered HbA1c (a measure of average blood sugar over three months) by 0.38 to 1.07 percentage points more than comparison treatments. For weight loss specifically, the higher-dose version of the same drug produced losses of roughly 15% of body weight over about 16 months.
How Much Weight You Can Expect to Lose
The weight loss numbers from clinical trials are substantial. In the STEP 1 trial, participants without type 2 diabetes who took the 2.4 mg weekly dose (marketed as Wegovy, the same active ingredient as Ozempic at a higher dose) lost an average of 14.9% of their body weight over 68 weeks. The placebo group lost just 2.4%. That means a 220-pound person could expect to lose roughly 33 pounds, while someone on placebo would lose about 5.
When paired with intensive behavioral therapy in the STEP 3 trial, average weight loss reached 16.0%, compared to 5.7% with therapy alone. People with type 2 diabetes tend to lose less weight on semaglutide. In the STEP 2 trial, participants with diabetes lost 9.6% of their body weight at the 2.4 mg dose, versus 3.4% with placebo.
A head-to-head trial against liraglutide (another injectable in the same drug class) showed semaglutide was clearly superior: 15.8% weight loss versus 6.4% over 68 weeks. In real-world comparisons with tirzepatide (Mounjaro), which targets two gut hormones instead of one, Mounjaro produced greater average weight loss, and the gap widened the longer patients stayed on treatment.
How Well It Controls Blood Sugar
Ozempic was developed and approved as a diabetes medication, and the blood sugar data is strong. Across the SUSTAIN clinical trial program, the 0.5 mg dose lowered HbA1c by 0.32 to 0.79 percentage points more than comparator drugs, while the 1.0 mg dose achieved reductions of 0.38 to 1.07 percentage points beyond comparators. These are clinically meaningful differences. For many people with type 2 diabetes, this is enough to bring HbA1c below the 7% target that guidelines recommend.
Some people notice blood sugar improvements within the first few weeks. For most, though, the full effect on glucose control takes three to four months to become clear, partly because the dose is gradually increased during that period.
How Quickly Results Appear
Ozempic uses a slow dose escalation that shapes the timeline of results. You start at 0.25 mg once weekly for the first four weeks. This is not a therapeutic dose; it exists solely to let your body adjust and reduce side effects. After four weeks, the dose increases to 0.5 mg. If more blood sugar control is needed, your prescriber can bump it to 1 mg after another four weeks, and eventually to a maximum of 2 mg weekly.
Because of this gradual ramp-up, most people start seeing noticeable weight loss around three to four months in. The best results typically come between six months and a year. Blood sugar tends to respond a bit faster, with some improvement visible in the first month, though optimal glucose control often takes a few months to achieve.
Whether the Results Last
Two-year data from the STEP 5 trial shows that weight loss is well maintained as long as you keep taking the medication. At 104 weeks, participants on semaglutide had lost an average of 15.2% of their body weight, compared to 2.6% in the placebo group. More than three-quarters of people on semaglutide (77.1%) had lost at least 5% of their starting weight by the two-year mark, versus about a third on placebo.
The critical caveat is that these results depend on continued use. The drug works by mimicking a gut hormone that reduces appetite and slows stomach emptying. When you stop taking it, those effects fade, and most people regain a significant portion of the lost weight. This is not a sign of failure; it reflects the biology of how the drug works. For most people, semaglutide is a long-term medication, not a short course.
Cardiovascular Protection
Beyond blood sugar and weight, semaglutide reduces the risk of serious cardiovascular events. Combined data from two large cardiovascular outcome trials showed a 24% reduction in the risk of major events like heart attack, stroke, and cardiovascular death compared to placebo (hazard ratio of 0.76). This benefit was consistent across different levels of cardiovascular risk.
The 2026 American Diabetes Association guidelines now recommend GLP-1 receptor agonists like semaglutide specifically for cardiovascular risk reduction in people with type 2 diabetes and kidney disease, and for prevention and management of heart failure in certain patients with diabetes and obesity. The drug has also earned guideline recommendations for people with type 2 diabetes and fatty liver disease progressing toward liver scarring.
Side Effects and Tolerability
Gastrointestinal side effects are the main trade-off. In clinical trials of the 2.4 mg dose, 43.9% of participants experienced nausea (versus 16.1% on placebo), 29.7% had diarrhea, 24.5% had vomiting, and 24.2% reported constipation. These numbers are high, but context matters: most GI symptoms are mild to moderate and peak during dose increases. They typically improve as your body adjusts over several weeks.
The slow titration schedule exists specifically to minimize these effects. Starting at the lowest dose and increasing gradually gives your digestive system time to adapt. Eating smaller meals, avoiding high-fat foods, and stopping eating when you feel full (rather than finishing a plate) all help. A minority of people find the side effects intolerable and discontinue, but most are able to manage them through the adjustment period.
How Ozempic Compares to Mounjaro
The most common comparison is between Ozempic (semaglutide) and Mounjaro (tirzepatide). Both are weekly injections, but they work slightly differently. Ozempic activates one gut hormone receptor, while Mounjaro activates two. In real-world data published in JAMA Internal Medicine, people on Mounjaro lost significantly more weight than those on Ozempic, and the difference grew over time.
That said, both medications produce results that would have been considered remarkable just a decade ago. The choice between them often comes down to insurance coverage, availability, and individual response. Some people do better on one than the other, and there is no reliable way to predict which will work best for a given person before trying it.